Perspective Therapeutics (CATX) 10-Q 14 Nov 17 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2017	Nov. 10, 2017
Document Information [Line Items]
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	728,387
Trading Symbol	isr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		55,017,419
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 3,956	$ 5,932
Certificates of deposit (Note 3)	3,300	3,039
Accounts receivable, net of allowance for doubtful accounts of $26 and $26, respectively	743	726
Inventory	453	323
Prepaid expenses and other current assets	414	271
Total current assets	8,866	10,291
Property and equipment, net	1,090	1,054
Restricted cash	181	181
Inventory, non-current	427	513
Other assets, net of accumulated amortization	217	230
Total assets	10,781	12,269
Current liabilities:
Accounts payable and accrued expenses	811	630
Accrued protocol expense	65	75
Accrued radioactive waste disposal	11	125
Accrued payroll and related taxes	34	138
Accrued vacation	146	138
Total current liabilities	1,067	1,106
Long-term liabilities:
Asset retirement obligation	568	561
Total liabilities	1,635	1,667
Commitments and contingencies (Note 8)
Shareholders' equity:
Common stock, $.001 par value; 192,998,329 shares authorized; 55,017,419 and 55,017,419 shares issued and outstanding	55	55
Additional paid-in capital	83,241	83,151
Accumulated deficit	(74,150)	(72,604)
Total shareholders' equity	9,146	10,602
Total liabilities and shareholders' equity	10,781	12,269
Series A Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value, issued	0	0
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value, issued	0	0
Series C Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value, issued	0	0
Series D Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value, issued	$ 0	$ 0

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Allowance for doubtful accounts receivable, current	$ 26	$ 26
Preferred stock, shares authorized (in shares)	7,001,671	7,001,671
Preferred stock, shares allocated (in shares)	7,001,671	7,001,671
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	192,998,329	192,998,329
Common stock, shares issued (in shares)	55,017,419	55,017,419
Common stock, shares outstanding (in shares)	55,017,419	55,017,419
Series A Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares allocated (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065
Preferred stock, shares allocated (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065
Series C Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares allocated (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	1,671	1,671
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares allocated (in shares)	1,671	1,671
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Product sales, net	$ 1,211	$ 1,081
Cost of product sales	946	1,033
Gross profit	265	48
Research and development
Propriety research and development	287	172
Collaboration arrangement, net of reimbursement	75
Total research and development	362	172
Sales and marketing	614	524
General and administrative	841	927
Total operating expenses	1,817	1,623
Operating loss	(1,552)	(1,575)
Non-operating income:
Interest income, net	6	30
Change in fair value of warrant derivative liability		27
Other income		20
Non-operating income, net	6	77
Net loss	(1,546)	(1,498)
Preferred stock dividends	(3)	(3)
Net loss applicable to common shareholders	$ (1,549)	$ (1,501)
Basic and diluted loss per share (in dollars per share)	$ (0.03)	$ (0.03)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	55,017	55,011

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,546)	$ (1,498)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense	18	16
Loss on equipment disposals		5
Amortization of other assets	13	10
Change in fair value of warrant derivative liability		(27)
Accretion of asset retirement obligation	7	7
Share-based compensation	90	70
Changes in operating assets and liabilities:
Accounts receivable, gross	(17)	31
Inventory	(44)	(39)
Prepaid expenses and other current assets	(143)	41
Accounts payable and accrued expenses	181	(118)
Accrued protocol expense	(10)	28
Accrued radioactive waste disposal	(114)	12
Accrued payroll and related taxes	(104)	98
Accrued vacation	8	11
Net cash used by operating activities	(1,661)	(1,353)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(54)	(147)
Additions to other assets		(151)
Proceeds from maturity of certificates of deposit	3,043
Purchases of and interest from certificates of deposit	(3,304)	(29)
Net cash used by investing activities	(315)	(327)
Net decrease in cash and cash equivalents	(1,976)	(1,680)
Cash and cash equivalents, beginning of quarter	5,932	10,139
CASH AND CASH EQUIVALENTS, END OF QUARTER	$ 3,956	$ 8,459

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries , referred to herein as “IsoRay” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10 June 30, 2017 . The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) . Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not Certain prior period amounts have been reclassified to conform to the current period ’s presentation. The results of operations for the periods presented may not may 2018 0%.

Note 2 - New Accounting Standar

Note 2 - New Accounting Standards	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	2. New Accounting Standards In May 2014, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014 09 605 10 five first 2019, first 2018. first 2019 2014 09 not In July 2015, No. 2015 11: ’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. July 1, 2017. not In N ovember 2015, 2015 17 July 1, 2017. not In February 2016, 2016 02 842 nize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for annual and interim reporting periods beginning after December 15, 2018. first 2020. In August 2016, No. 2016 15 230 lassification of Certain Cash Receipts and Cash Payments. The update provides guidance on classification for cash receipts and payments related to eight December 15, 2017, Other accounting standards that have been issued or proposed by FASB that do not not not not

Note 3 - Certificates of Deposi

Note 3 - Certificates of Deposit	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Cost-method Investments, Description [Text Block]	3. Certificates of Deposit Certificate of Deposit Account Registry Service (CDARS) is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 poration (FDIC). That institution utilizes the CDARS system to purchase certificates of deposit at other financial institutions while keeping the investment at each institution fully insured by the FDIC. CDARS held by the Company as of September 3 0, 2017 June 30, 2017 As of September 30, 2017 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 825 $ 825 $ 1,650 $ - As of June 30, 201 7 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 3,039 $ - $ - $ -

Note 4 - Loss Per Share

Note 4 - Loss Per Share	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Loss per Share Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not equivalents. At September 30, 2017 2016, not , as those would be antidilutive due to the Company’s net loss position. Securities not September 30, 2017 2016, September 30 , 2017 2016 Series B preferred stock 59 59 Common stock warrants - 230 Common stock options 3,395 2,609 Total potential dilutive securities 3,454 2,898

Note 5 - Inventory

Note 5 - Inventory	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventory Inventory consisted of the following at September 30, 2017 June 30, 2017 ( September 30 , June 30, 2017 2017 Raw materials $ 339 $ 191 Work in process 94 121 Finished goods 20 11 Total inventory, current $ 453 $ 323 September 30 , June 30, 2017 2017 Enriched barium, non-current $ 347 $ 470 Raw materials, non-current 80 43 Total inventory, non-current $ 427 $ 513 Inventory, non-current is raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not . On August 25, 2017, Medical”) entered into a Consignment Agreement and related Services Agreement with MedikorPharma-Ural LLC (“Medikor”). Pursuant to the Consignment Agreement, Medical has consigned its inventory of enriched barium carbonate to Medikor. It is expected that beginning in November, 2017, third 131. 131. third 131 third 131 Medical anticipates obtaining enough Cesium- 131 4,000 131 ten no third 131

Note 6 - Property and Equipment

Note 6 - Property and Equipment	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment Property and equipment consisted of the following at September 30, 2017 June 30, 2017 ( September 30 , June 30, 2017 2017 Land $ 366 $ 366 Equipment 3,776 3,776 Leasehold improvements 4,134 4,130 Other 1 422 373 Property and equipment 8,698 8,645 Less accumulated depreciation (7,608 ) (7,591 ) Property and equipment, net $ 1,090 $ 1,054 1 – Represents items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet. Also included at September 30, 2017 June 30, 2017

Note 7 - Share-based Compensati

Note 7 - Share-based Compensation	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Share-Based Compensation The following table presents the share-based compensation expense recognized during the three September 30, 2017 2016 Three Months ended September 30, 2017 2016 Cost of product sales $ 16 $ 27 Research and development expenses 19 8 Sales and marketing expenses 17 15 General and administrative expenses 38 20 Total share-based compensation $ 90 $ 70 As of September 30, 2017, $807 ,000 1.39 A summary of stock options within the Company ’s share-based compensation plans as of September 30, 2017 Weighted Weighted Average Number of Exercise Contractual Intrinsic As of September 30, 2017 Options Price Term (Years) Value Outstanding 3,395 $ 0.76 7.71 $ 67 Vested and expected to vest 3,290 $ 0.76 7.66 $ 67 Vested and exercisable 1,760 $ 0.90 5.82 $ 67 There were no three September 30, 2017 2016, There were 75,000 no $33,000 0 three September 30, 2017 2016, There were no and 280,534 three September 30, 2017 2016, There were 59,666 35,336 three September 30, 2017 2016,

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Isotope Purchase Agreement In December 2015, 131 one ’s supply of Cs- 131. March 31, 2017, December 2016 December 31, 2017. October 23, 2017, 131 December 31, 2018 Research and Development - Collaborative Arrangement On March 13, 2017, rther develop a brachytherapy medical device for the treatment of cancerous tumors in the brain and to seek regulatory approval for the new product. As the project manager, Medical will incur all costs in connection with the collaboration project which has been shared equally by both parties as of November 8, 2016 December 2017 March 2018. 808 October 2017. During the quarte r ended September 30, 2017 June 30, 2017, $147,000 $65,000, As of September 30, 2017 June 30, 2017, $68,000 $66,000 Derivative Complaint related to Shareholder Value On September 29, 2016, No. 0:16 03297 named as defendants current and former IsoRay directors Dwight Babcock, Thomas LaVoy, Philip J. Vitale and Michael W. McCormick, alleging that they violated their fiduciary duties to IsoRay in connection with a press release allegedly containing false and misleading statements concerning the results from a peer reviewed study of its Cesium- 131 not On November 17, 2016, not ’s board. Rather than respond to the motion to dismiss, plaintiff filed an amended complaint on January 23, 2017. March 9, 2017. April 20, 2017, May 17, 2017. August 22, 2017, October 19, 2017,

Note 9 - Fair Value Measurement

Note 9 - Fair Value Measurements	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. Fair Value Measurements The following table sets forth the Company ’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands): Fair Value at September 30, 2017 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,956 $ 3,956 $ - $ - Fair Value at June 30, 2017 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,932 $ 5,932 $ - $ - The Company’s cash and cash equivalent instruments are classified within Level 1

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10 . Related Party Transaction s During the quarter ended June 30, 2016, ’s rebranding effort. Michael McCormick, a member of the Company Board of Directors, is a 1/3 September 30, 2016, $15,000 No September 30, 2017 .

Note 11 - Concentrations of Cre

Note 11 - Concentrations of Credit and Other Risks	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	11 . Concentrations of Credit and Other Risks One group of customers, facilities or physician practices has revenues that aggregate to greater than 10% Three months ended September 30 , September 30 , Facility 201 7 201 6 El Camino Hospital of Los Gatos, Fremont Surgery Center & other facilities 1 25.98 % 22.33 % 1 – This group of facilities individually each comprise less than 10% one The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necess ary.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	12 . Subsequent Events Media Advertising Agreement On October 3, 2017, Pursuant to the Agreement, the Consultant will introduce IsoRay to potential sources of media, marketing agreements, and/or strategic alliances, including but not not 180 may first 90 As compensation for the services, IsoRay will pay the Consultant $120,000 $20,000 $20,000 30, 60, 90, 120, 150 250,000 October 3, 2020, $0.54 250,000 90

Note 3 - Certificates of Depo18

Note 3 - Certificates of Deposit (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Cost Method Investments [Table Text Block]	As of September 30, 2017 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 825 $ 825 $ 1,650 $ - As of June 30, 201 7 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 3,039 $ - $ - $ -

Note 4 - Loss Per Share (Tables

Note 4 - Loss Per Share (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30 , 2017 2016 Series B preferred stock 59 59 Common stock warrants - 230 Common stock options 3,395 2,609 Total potential dilutive securities 3,454 2,898

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30 , June 30, 2017 2017 Raw materials $ 339 $ 191 Work in process 94 121 Finished goods 20 11 Total inventory, current $ 453 $ 323
Schedule of Inventory, Noncurrent [Table Text Block]	September 30 , June 30, 2017 2017 Enriched barium, non-current $ 347 $ 470 Raw materials, non-current 80 43 Total inventory, non-current $ 427 $ 513

Note 6 - Property and Equipme21

Note 6 - Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30 , June 30, 2017 2017 Land $ 366 $ 366 Equipment 3,776 3,776 Leasehold improvements 4,134 4,130 Other 1 422 373 Property and equipment 8,698 8,645 Less accumulated depreciation (7,608 ) (7,591 ) Property and equipment, net $ 1,090 $ 1,054

Note 7 - Share-based Compensa22

Note 7 - Share-based Compensation (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months ended September 30, 2017 2016 Cost of product sales $ 16 $ 27 Research and development expenses 19 8 Sales and marketing expenses 17 15 General and administrative expenses 38 20 Total share-based compensation $ 90 $ 70
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Weighted Weighted Average Number of Exercise Contractual Intrinsic As of September 30, 2017 Options Price Term (Years) Value Outstanding 3,395 $ 0.76 7.71 $ 67 Vested and expected to vest 3,290 $ 0.76 7.66 $ 67 Vested and exercisable 1,760 $ 0.90 5.82 $ 67

Note 9 - Fair Value Measureme23

Note 9 - Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value at September 30, 2017 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,956 $ 3,956 $ - $ - Fair Value at June 30, 2017 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,932 $ 5,932 $ - $ -

Note 11 - Concentrations of C24

Note 11 - Concentrations of Credit and Other Risks (Tables)	3 Months Ended
	Sep. 30, 2017
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Three months ended September 30 , September 30 , Facility 201 7 201 6 El Camino Hospital of Los Gatos, Fremont Surgery Center & other facilities 1 25.98 % 22.33 %

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual)	3 Months Ended
	Sep. 30, 2017
Effective Income Tax Rate Reconciliation, Percent	0.00%

Note 3 - Certificates of Depo26

Note 3 - Certificates of Deposit - Summary of Certificates of Deposit (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Under 90 Days [Member]
CDARS	$ 825	$ 3,039
For 91 Days to Six Months [Member]
CDARS	825
Six Months to 1 Year [Member]
CDARS	1,650
Greater than 1 Year [Member]
CDARS

Note 4 - Loss Per Share - Antid

Note 4 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive securities (in shares)	3,454	2,898
Series B Preferred Stock [Member]
Antidilutive securities (in shares)	59	59
Warrant [Member]
Antidilutive securities (in shares)		230
Employee Stock Option [Member]
Antidilutive securities (in shares)	3,395	2,609

Note 5 - Inventory - Current In

Note 5 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Raw materials	$ 339	$ 191
Work in process	94	121
Finished goods	20	11
Total inventory, current	$ 453	$ 323

Note 5 - Inventory - Noncurrent

Note 5 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Total inventory, non-current	$ 427	$ 513
Enriched Barium Inventory [Member]
Total inventory, non-current	347	470
Raw Materials [Member]
Total inventory, non-current	$ 80	$ 43

Note 6 - Property and Equipme30

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Sep. 30, 2017	Jun. 30, 2017
Property and equipment, gross		$ 8,698	$ 8,645
Less accumulated depreciation		(7,608)	(7,591)
Property and equipment, net		1,090	1,054
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		3,776	3,776
Leasehold Improvements [Member]
Property and equipment, gross		4,134	4,130
Other [Member]
Property and equipment, gross	[1]	$ 422	$ 373
[1]	Represents items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet. Also included at September 30, 2017 and June 30, 2017 are costs associated with automation of production processes and advance planning and design work on the Company’s new production facility.

Note 7 - Share-based Compensa31

Note 7 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 807,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 142 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	75,000	0
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value	$ 33,000	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0	280,534
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	59,666	35,336

Note 7 - Share-based Compensa32

Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Total share-based compensation	$ 90	$ 70
Cost of Sales [Member]
Total share-based compensation	16	27
Research and Development Expense [Member]
Total share-based compensation	19	8
Selling and Marketing Expense [Member]
Total share-based compensation	17	15
General and Administrative Expense [Member]
Total share-based compensation	$ 38	$ 20

Note 7 - Share-based Compensa33

Note 7 - Share-based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	3,395
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.76
Outstanding, weighted average contractual term (Year)	7 years 259 days
Outstanding, intrinsic value | $	$ 67
Vested and expected to vest, options (in shares) | shares	3,290
Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares	$ 0.76
Vested and expected to vest, weighted average contractual term (Year)	7 years 240 days
Vested and expected to vest, intrinsic value | $	$ 67
Vested and exercisable, options (in shares) | shares	1,760
Vested and exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 0.90
Vested and exercisable, weighted average contractual term (Year)	5 years 299 days
Vested and exercisable, intrinsic value | $	$ 67

Note 8 - Commitments and Cont34

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016
Research and Development Expense	$ 362,000		$ 172,000
Receivables, Net, Current	743,000	$ 726,000
Collaborative Development Agreement [Member]
Research and Development Expense	147,000	65,000
Collaborative Development Agreement [Member] | GammaTile LLC [Member]
Receivables, Net, Current	$ 68,000	$ 66,000

Note 9 - Fair Value Measureme35

Note 9 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Cash and cash equivalents	$ 3,956	$ 5,932
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	3,956	5,932
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents

Note 10 - Related Party Trans36

Note 10 - Related Party Transactions (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Go Intellectual Capital LLC [Member]
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party	$ 0	$ 15,000

Note 11 - Concentrations of C37

Note 11 - Concentrations of Credit and Other Risks - Revenue Concentration (Details)		3 Months Ended
		Sep. 30, 2017	Sep. 30, 2016
Sales Revenue, Goods, Net [Member]
El Camino Hospital of Los Gatos, Fremont Surgery Center & other facilities	[1]	25.98%	22.33%
[1]	This group of facilities individually each comprise less than 10% of total Company product sales. They are serviced by the same physician group, one of whom is our Medical Director.

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member] - A1 & J Media [Member]	Oct. 03, 2017USD ($)$ / sharesshares
Service Agreement Amount, Cash	$ 120,000
Service Agreement Amount, Payable Tranche One	20,000
Service Agreement Amount, Payable Tranche Two	20,000
Service Agreement Amount, Payable Tranche Three	20,000
Service Agreement Amount, Payable Tranche Four	20,000
Service Agreement Amount, Payable Tranche Five	20,000
Service Agreement Amount, Payable Tranche Six	$ 20,000
Warrants Issued in Tranche One [Member]
Class of Warrant or Right, Issued for Services | shares	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.54
Warrants Issued in Tranche Two [Member]
Class of Warrant or Right, Issued for Services | shares	250,000